Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05109 (
S100A8
)
1,212
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Chemotherapy plays an important role in the treatment of breast cancer. However, chemoresistance remains the main obstacle for effective treatment, leading to poor prognosis. This study aims to investigate the value of detection of
S100A8
and
ASAH1
in predicting the chemotherapy response. Miller and Payne grades were used to assess the chemotherapy response in breast cancers. The expression of
S100A8
and
ASAH1
, as well as ER, PR, HER2 and Ki-67 were assessed by immunohistochemical staining in 120 cases of non-special type invasive ductal carcinoma (IDC-NOS).
S100A8
expression was higher in chemosensitive breast cancers than chemoresistant ones. Moreover,
S100A8
expression was significantly correlated with the molecular subtypes and histological grade, but not with patients' age, tumor size and lymph nodes status. However, there was no significant difference in
ASAH1
expression between chemoresistant and chemosensitive group. We also found that higher
ASAH1
expression was correlated with positive lymph nodes status, but not with age, tumor size, molecular subtypes and histological grade.
S100A8
was valuable in predicting chemotherapy response in breast cancers. The expression of
ASAH1
was associated significantly with lymph nodes metastasis, indicating that
ASAH1
may serve as a biomarker to predict patients' lymph nodes status in breast cancers.
...
PMID:The value of detection of S100A8 and ASAH1 in predicting the chemotherapy response for breast cancer patients. 2932 Jul 52